NCT05032820 2026-03-05
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
Phase 2 Completed
Clinical Trials
6 trialsNCT02728102 2024-05-07
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT02322320 2020-05-11
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00525447 2014-10-09
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
Seagen Inc.
Phase 1 Completed
NCT00502112 2011-10-12
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Seagen Inc.
Phase 1 Completed